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Abstract
Background
Clostridium difficile infection (CDI) is a major cause of hospital-acquired diarrhea. Second-
ary bile acids were shown to confer resistance to colonization by C. difficile. 7α-dehydroxyla-
tion is a key step in transformation of primary to secondary bile acids and required genes
have been located in a single bile acid-inducible (bai) operon in C. scindens as well as in
C. hiranonis, two Clostridium sp. recently reported to protect against C. difficile colonization.
Aim
To analyze baiCD gene abundance in C. difficile positive and negative fecal samples.
Material & methods
A species-specific qPCR for detecting baiCD genes was established. Fecal samples of
patients with CDI, asymptomatic toxigenic C. difficile colonization (TCD), non-toxigenic C.
difficile colonization (NTCD), of C. difficile negative (NC) patients, and of two patients before
and after fecal microbiota transplantation (FMT) for recurrent CDI (rCDI) were tested for the
presence of the baiCD genes.
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Results
The prevalence of the baiCD gene cluster was significantly higher in C. difficile negative
fecal samples than in samples of patients diagnosed with CDI (72.5% (100/138) vs. 35.9%
(23/64; p<0.0001). No differences in baiCD gene cluster prevalence were seen between NC
and NTCD or NC and TCD samples. Both rCDI patients were baiCD-negative at baseline,
but one of the two patients turned positive after successful FMT from a baiCD-positive
donor.
Conclusion
Fecal samples of CDI patients are less frequently baiCD-positive than samples from asymp-
tomatic carriers or C. difficile-negative individuals. Furthermore, we present a case of baiCD
positivity observed after successful FMT for rCDI.
Introduction
Clostridium difficile infection (CDI) is the major cause of hospital-acquired diarrhea and is
associated with significant morbidity and mortality [1–3]. Broad spectrum antibiotic treatment
disrupts the commensal host microbiota, thereby increasing the risk for CDI. A crucial patho-
physiologic concept in this context is a breakdown of colonization resistance [4–6], which
involves direct and indirect mechanisms. Direct mechanisms include the competition for
nutrients, the conversion of nutrients (e.g. small chain fatty acids, SCFA) or host metabolites to
other compounds (e.g. secondary bile acids), as well as the inhibition of C. difficile by the pro-
duction of primary microbial products (e.g. thuricin CD produced by Bacillus thuringiensis)
[4, 7–10]. Indirect inhibition relates to microbiota-induced host immune reaction to control
C. difficile colonization and proliferation. Microbe-associated molecular patterns (MAMPs)
and danger-associated molecular patterns (DAMPs) induce either a homeostatic or an inflam-
matory response with involvement of adaptive (e.g. immunoglobulins) or innate (e.g. antimi-
crobial peptides) immune modulatory pathways [4, 11].
Among these mechanisms, the role of bile acids has been met with increasing interest.
While primary bile acids like taurocholate can induce C. difficile germination, secondary bile
acids like lithocholic and ursodeoxycholic acid (UDCA) have an inhibitory effect on germina-
tion of the bacteria [12, 13]. Recently, the C. difficile bile acid germinant receptor CspC, a
germination-specific protease, has been identified as the link between bile acid-mediated ger-
mination and C. difficile infection in a hamster model [14].
The capability of bile acid transformation from primary to secondary bile acids is limited to
a small subset of gut bacteria [15–17]. Within the Clostridium cluster XIVa, published evidence
mainly involves Clostridium scindens and Clostridium hylemonae [18, 19]. Eight separate pro-
teins are required to perform the bile acid biotransformation [20, 21]. One key enzyme of this
secondary bile acid biosynthesis cascade is a stereo-specific NAD(H)-dependent 3-dehydro-
4-bile acid oxidoreductase, encoded by the baiCD gene cluster, located within the bai operon
[21, 22]. The level of the secondary bile acid deoxycholic acid is regulated by the concentration
of bile acid 7α-dehydroxylating gut bacteria [23]. Within the Clostridium cluster XIVa, C. scin-
dens and C. hiranonis have an at least 10 times higher 7α-dehydroxylating activity than other
clostridial species [15, 24, 25]. Intriguingly, it has been reported that antibiotic therapy and
subsequent disruption of the commensal microbiota lead to a decrease in the number of 7α-
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dehydroxylating bacteria, and to a shift of the fecal bile acid pool from secondary to primary
bile acids [26–29]. In 2015, Buffie et al. identified several species (Clostridium scindens, Pseudo-
flavonifractor capillosus, Barnesiella spp. and Blautia hansenii) mediating CDI resistance in a
mouse model, and corroborated these findings in a small number of hematologic patients [30].
In particular, C. scindens was negatively associated with CDI, which may be owing to its role in
secondary bile acid biosynthesis.
Bile acid 7α-dehydroxylation via baiCD gene cluster encoded 3-dehydro-4-bile acid oxido-
reductase is thus likely a decisive component of colonization resistance against C. difficile.
Despite the high pathophysiological relevance demonstrated in preclinical studies, the role of
this metabolic step in patients with C. difficile infection is largely unclear. The aim of the pres-
ent study was to investigate the abundance of the baiCD gene cluster in patients with CDI or
C. difficile colonization, and in controls as well as in patients undergoing fecal microbiota
transplantation for recurrent CDI.
Material and methods
Sample collection
Fecal samples were collected from patients aged 18 years within 48 hours of admission to
one of five German university-affiliated hospitals (Hannover, Tu¨bingen, Munich, Cologne and
Lu¨beck) and were stored directly at -80˚C within a prospective, observational multicenter
study (SPECTRUM), which aims at the identification of clinical and microbiota-associated
risk factors for C. difficile infection (CDI) and colonization. The study was performed accord-
ing to GCP guidelines as well as the ethical guidelines of the Declaration of Helsinki. All partic-
ipants gave written informed consent. Detailed informations about the SPECTRUM study are
given in the German Clinical Trials Register (www.drks.de, registered as DRKS00005335).
Approval for the anonymous assessment of sample collection and patient data was granted by
the ethics committees of all contributing study sites (internal approval number and approval
data in parentheses): Hannover (No. 6444, 2013), Tu¨bingen (No. 497/2013BO2, 2013), Munich
(No. 5906/13, 2013), Cologne (No. 13–282, 2013) and Lu¨beck (No. 15–088, 2015).
In addition, out of the daily microbiological routine, 72 fecal samples of symptomatic
patients tested positive for toxigenic Clostridium difficile (CDI) either by toxin B ELISA or by
conventional culture were analyzed. These samples were negative for other tested pathogens
(Salmonella spp., Shigella spp., Yersinia spp., Campylobacter spp.) to avoid bias in fulfilling
the CDI case definition (diarrhea and positive toxin test, [31]). Approval for the anonymous
assessment of sample collection and patient data was granted by the ethics committee of Han-
nover Medical School (No. 3378–2016, 2016).
GDH test and Clostridiumdifficile toxin assay performance
For initial Clostridium difficile screening, 189 fecal samples from the SPECTRUM study were
tested for GDH (glutamate dehydrogenase) antigen, which indicates the presence of C. difficile
(toxin-positive and toxin-negative strains alike), by an EIA assay according to the manufactur-
er’s instructions (GDH EIA, C. DIFF CHEK™—60, Techlab, Blacksburg, USA). GDH EIA
assays possess a sensitivity of 85%–95% and a specificity of 89%–99% [32, 33]. GDH test posi-
tive fecal samples were tested by PCR for toxin A (tcdA) and B (tcdB) to differentiate between
patients colonized with non-toxigenic C. difficile (NTCD; GDH test positive, toxin negative) or
patients asymptomatically colonized with toxigenic C. difficile (TCD; GDH test positive, toxin
positive) [34–41]. PCR targeting of the toxin genes for toxin A (tcdA) and B (tcdB) was per-
formed with a standardized in-house real-time PCR assay on a CFX96™ Real-Time PCR Detec-
tion System (Bio-Rad Laboratories, Hercules, CA, USA) for all stool samples of patients with
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positive GDH test [42, 43]. Toxin PCR positivity was defined as a positive result for tcdA, tcdB,
or both. We note that the detection of the toxin genes cannot predict the expression of toxins
in vitro or in vivo with certainty since the expression is controlled by multiple transcriptional
regulators, including TcdR. Nevertheless, carriage of the toxin genes is a prerequisite and the
most important known predictor of toxin production.
DNA extraction from stool samples
DNA was extracted with the QIAcube DNA extraction system according to the manufacturer’s
instructions (modified QIAamp DNA Mini kit protocol for tissue extraction (Qiagen, Hilden,
Germany)) [44]. Briefly, approximately 100 mg stool was vortexed with 600 μl S.T.A.R. buffer
(Roche, Mannheim, Germany) and 60 μl chloroform before being spun for 1 min. 200 μl of the
supernatant was transferred into 2 ml microcentrifuge tubes, pre-filled with 0.1 mm (~0.5 g)
and 0.3 mm (~0.35 g) beads and incubated with 500 μl buffer ASL for 5 min at 70˚C. Homoge-
nization was performed with Precellys24™ (Bertin Corp., Rockville, USA), followed by a centri-
fugation step for 2 minutes. 350 μl of supernatant was used for DNA extraction. The DNA was
eluted with 2 × 50 μl aliquots of Buffer AE and stored at 4˚C.
baiCD gene cluster qPCR
BaiCD gene cluster qPCR was performed with a CFX 96™ Real-Time PCR Detection System
(Bio-Rad Laboratories, Hercules, CA, USA) and Bio-Rad CFX Manager 3.1 Software. BaiCD
gene cluster-specific primers were used to target C. scindens and C. hiranonis with modified
primers based on the publication by Ou et al. [45]. These published baiCD gene cluster primer
pairs were modified by aligning the baiCD genes DNA sequence from C. scindens VPI 12708
[46] and C. hiranonis TO-931 [16] using CLC genomics Workbench 8.5.1. (Qiagen, Hilden,
Germany). In CLC genomics Workbench 8.5.1 alignment with annotated sequences of the
baiCD genes (www.ncbi.nlm.nih.gov) of different strains (sequences of C. scindens VPI 12708,
C. scindens VE202-05, C. scindens ATCC35704 (DSM 5676), C. hiranonis TO-931 (DSM
13275) and C. hylemonae TN271 (DSM 15053), were used to specify the published primers (S2
Fig). We sequenced C. scindens ATCC35704 (DSM 5676) and C. hiranonis TO-931 (DSM
13275). Our sequence of the baiCD genes in contig 6 was 100% identical with the published
sequences (S2 Fig).
The specific primers including the forward primer baiCD-F (50-CAGCCCRCAGATGTTCT
TTG-30) and the reverse primer baiCD-R (50-GCATGGAATTCHACTGCRTC-30) were identi-
fied to be the largest and most specific potential primers in the baiCD genes and were synthe-
sized commercially (TIB Molbiol, Berlin, Germany). Performance and optimal annealing
temperatures of the PCR primers were first tested with gradient PCR on the CFX 96™ Real-
Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA). The highest primer
efficiency was seen at 400 nM for the forward primer and 600 nM for the reversed primer. The
cycling conditions were as follows: 95˚C for 15 min followed by 45 cycles of 94˚C for 15 s,
primer-specific annealing temperature at 60˚C for 30 s, and 72˚C for 30 s. After amplification,
a dissociation step was included to analyze the melting profile of the amplified products. Ten-
fold dilution series of a specially designed gBlock Gene fragments (Integrated DNA Technolo-
gies, Coralville, IA) standard for the respective bacterial group or species were run along with
the samples.
The gBlock Gene Fragments (Integrated DNA Technologies (IDT), Coralville, IA) contain-
ing the baiCD gene cluster qPCR target were purchased to estimate the detection limits of
qPCR limits. A 10 fold serial dilution of the gBlock Gene Fragment (2 x 107 to 2 x 100 copies/μl
per reaction) was run on every baiCD gene cluster qPCR assay to determine the slope. The
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prevalence of baiCD-positive samples was done by endpoint measurement. The fecal samples
were counted as positive for baiCD when the reaction crossed the fluorescence threshold, a
fluorescent signal significantly above the background fluorescence (usually 10 times the stan-
dard deviation of the baseline [47]). For quantification, the copy number had to be in the
range of standard (ten-fold dilution series of a specially designed gBlock Gene fragments
(IDT) standard for the respective bacterial group or species, which were run along with the
samples). Four samples in the NC group, 1 sample in the NTCD and the TCD group and 2
samples in the CDI group were excluded due to low copy numbers from final analysis.
We controlled baiCD-negative fecal samples for PCR inhibitors, because inhibitors within
the samples could interfere with the PCR by interacting directly with DNA, degrading or trap-
ping the target DNA or blocking the activity of the polymerase. Common PCR inhibitors are
the used material in the laboratory, food ingredients or the environmental background mate-
rial [48–50]. For the detection of PCR inhibition, we used the housekeeping gene β-actin,
which is a reliable internal reference gene. The gene-specific primers for β-actin for the inter-
nal control included Humu ACT_F (5´-CTTCAACACCCCAGCCATGT-3) and Humu
ACT_2R (5´-TCTCCTTAATGTCACGCAGA-3). The mix included 10 μl of 2x Quanti-Tect
SYBR Green Master Mix 0.3 μl of the forward and 0.3 μl of the reverse primer, 5 μl of target
DNA and 4.4 μl of water. A known amount of positive control DNA is amplified with the sam-
ple, and inhibition is observed by a change in the quantitation of positive control DNA. Gastric
cancer cell lines AGS were used as positive controls. The PCR conditions included: 95˚C for
15 min followed by 45 cycles of denaturation at 94˚C for 15 seconds, primer-specific annealing
temperature at 60˚C for 30 seconds, and an elongation step at 72˚C for 30 seconds. The
annealing temperature of 60˚C was chosen because of required compatibility for C.scindens
and C. hiranonis PCR assays. For our final analysis, we excluded samples which were baiCD-
negative as well as negative for the internal reference housekeeping gene β-actin, in the
assumption, that the inhibitors affecting the target DNA and the species-specific primers for
the baiCD genes could not bind.
DNA extraction from bacteria
The specificity of the baiCD gene cluster primers was confirmed against the non-target test
bacteria; otherwise, results from the sequence searches against bacteria DNA databases were
relied upon. The non-target test bacteria included Streptococcus mitis (in-house strain isolation
out of the biliary tract), Clostridium difficile (ATCC 700057), Escherichia coli ATCC 25922,
Eubacterium aerofaciens (in-house strain isolation out of douglas pouch), Bacillus fragilis
ATCC 25285, Clostridium perfringens ATCC 13124, Clostridium hylemonae DSM 15053, Clos-
tridium sordellii DSM 2141, Lactobacillus rhamnosus (in-house strain isolation out of feces), as
well as Blautia hansenii DSM 20583. Clostridium scindens DSM 5676 and Clostridium hiranonis
DSM 13275 were used as positive controls (S3 Fig). DNA extraction from bacteria was per-
formed according to the manufacturer’s instructions (QIAamp DNA Mini kit protocol for
bacteria, Qiagen, Hilden, Germany) [51]. Briefly, harvested bacteria were centrifuged for 10
min. The bacterial pellet was resuspended in 180 μl enzymatic lysis buffer (Qiagen, Hilden,
Germany) and incubated for 30 min at 37˚C. The next step included 25 μl of proteinase K
(Qiagen, Hilden, Germany) and 200 μl AL buffer (Qiagen, Hilden, Germany) and mixed with
the enzymatic lysis buffer. After this step, 200 μl ethanol (96%) was added to the sample and
mixed thoroughly by vortexing. The precipitate mix was pipetted into the QIAamp DNA Mini
spin column and centrifuged for 1 min. 500 μl Buffer AW1 (Qiagen, Hilden, Germany) was
added and centrifuged for 1 min. 500 μl buffer AW2 (Qiagen, Hilden, Germany) was added
and centrifuged for 3 min. The last step included the placement of the QIAamp DNA Mini
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spin column in a clean 1.5 ml or 2 ml microcentrifuge tube with 200 μl Buffer AE (Qiagen, Hil-
den, Germany) directly added onto the spin column membrane. The spin column was incu-
bated at room temperature for 1 min and then centrifuged to elute. The purity and yield of the
DNA were assessed spectrophotometrically (Nanodrop 1000; Thermo Fisher Scientific, Wal-
tham, MA USA) by calculating the A260/A280 ratios to determine DNA concentrations.
Quantification of 16S rDNA copy number density by rtPCR
As a proof of principle, to exclude a potential influence of stool consistency on the number of
baiCD genes, we assessed the total bacterial concentration by 16S rDNA qPCR in a random
number of stool samples (nine stool samples of Bristol Stool Scale (BSS) 1–4, 18 stool samples
of BSS 5–6 and 19 stool samples of BSS 7). The BSS consists out of seven consistency categories
of human feces, starting with low scores for hard stools and longer colon transit times whereas
higher scores correspond to loose watery stools and fast transit times [52]. The first two types
indicate constipation, 3 and 4 indicate formed/normal stool, 5 and 6 indicate unformed/liquid
stool and 7 indicate diarrhea. We therefore phenotypically grouped the fecal samples into
three groups: 1–4, 5–6 and 7 according to the part of water and solids in the stool. We used a
previously published set including the forward primer Uni331F (50-TCCTACGGGAGGCAGC
AGT-30), the reverse primer Uni797R (50-GGACTACCAGGGTATCTATCCTGTT-30) and the
probe ((6-FAM)-5«-CGTATTACCGCGGCTGCTGGCAC-(3-BBQ)) for the 16S rDNA
PCR [53]. Real-time PCR was performed in the LightCycler1480 Real-Time PCR System
(Roche Diagnostic, Mannheim, Germany) and LightCycler 480 Software release 1.5.1.62. PCR
reactions contained 18 μl of master mix and 2 μl of template DNA. The final reaction mixture
contained: 8 μl of 2.5x Molzym Master Mix (Molzym GmbH & Co.KG, Bremen, Germany),
0.3 μM of the primers Uni331F and Uni797R, 0.15 μM of the probe, 0.8 μl of Molzym Poly-
merase, 100 μg/μl BSA (New England Biolabs) and 2 μl of template DNA. PCR conditions
included an initial incubation step of 5 minutes at 95˚C, followed by 45 cycles of denaturation
at 95˚C for 10 seconds, followed by annealing and elongation at 60˚C for 60 seconds. The
amplification protocol ended with a cooling period of 40˚C for 30 seconds.
Reproducibility
For the preparation of the 16S rDNA gene standard Escherichia coli DNA was used for deter-
mining bacterial number by real-time PCR. The set included the forward primer 285F 5´-GAG
AGT TTG ATC CTG GCT CAG–3` and the reverse primer 261R 5´-GAG GTG ATC CAG
CCG CA-3´. A 1533 bp sized amplicon was generated via PCR. The PCR reactions contained
45 μl of master mix and 5 μl of template DNA. The final reaction mixture contained: 5 μl of 10x
Buffer (18 mM MgCl2), 1 μl of dNTPs (10 mM each), 2 μl of 285F (10 pmol/μl), 2 μl of 261R (10
pmol/μl), 0,5μl of Faststart HiFi Polymerase Roche (5U/μl), 34,5 μl of water and 5 μl of DNA.
The copy number was calculated using Avogadro’s number. Standards were serially diluted,
extracted as described above, and subjected to the 16S PCR assay by two different technicians as
well as the patient samples on three separate days. Non-template control (NTC) were included
in all tests (S1 Fig).
Donor selection, stool preparation and fecal microbiota transfer (FMT)
Out of routinely performed FMTs for recurrent C. difficile infection, we analyzed fecal samples
of two patients before and after FMT. Donor selection was performed in accordance with the
criteria of Paramsothy et al. [54] and approved by the local ethics committee (request of
expanded access for each patient (30.03.2015)). Fresh donor stool was processed not later than
2 h after collection, and the transfer to the recipient was performed within 6 h after stool
BaiCD gene cluster abundance in CDI
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donation. In accordance with the systematic review of Cammarota et al. [55] and the published
statement of the European consensus conference on fecal microbiota transfer [56], we col-
lected approximately 100 g of donor fecal material and transferred it into a standard commer-
cial blender. Subsequently, 200 ml of sterile normal saline (0.9% sodium chloride) were added,
and the blender content was homogenized. The resulting slurry was filtered through different
sized sieves and transferred in five 50 ccm syringes. The supernatant was administrated
directly via colonoscopy in the ascending part of the colon in our endoscopy unit. The patients
were prepared with local standard medication for colonoscopy (Oralav1; Moviprep1) and in
the morning of FMT, the patients received loperamide to decrease large bowel movements.
Any previously administered antibiotic treatment was stopped 48 h before FMT.
Statistical analysis
Differences in baiCD gene cluster abundance between the four study groups (NC, NTCD,
TCD and CDI) were assessed using the chi-square test for categorical variables (binary variable
or dichotomous variable, “yes” or “no” indicating the presence or absence of the baiCD genes).
Post-hoc analysis was performed by pairwise comparisons using Fisher’s exact test. In addi-
tion, categorical variables from the table of baseline patients’ characteristics were used for sta-
tistical analysis, i. e. gender (male or female), the presence or absence of diarrhea, CDI,
antibiotics or proton-pump inhibitors. For analyzing the presence or absence of the baiCD
genes in fecal samples, we used a double approach. If the results were inconsistent, we would
re-run the PCR protocol with this sample. The reproducibility of the 16S rDNA PCR was
proven in 4 different patient samples by two different technicians on three separate days (S1
Fig). One-way ANOVA was performed on the gene copy numbers of the different groups.
Unpaired t-test was performed for the relative abundance of baiCD genes in fecal samples.
Data were displayed in box-and-whiskers plots showing the median, interquartile range, and
range from minimum to maximum.
All p values were two-sided and the level of significance was set at p<0.05. In case of pair-
wise comparison within the four groups, the p-value was not adjusted for multiple testing as
we assumed our analysis being hypothesis generating. All data were analyzed using GraphPad
Prism 6.0 (GraphPad Software Inc., La Jolla, CA, USA).
Results
Patient characteristics
Overall, four sample groups were available for further analysis (NC (n = 148), NTCD (n = 14),
TCD (n = 27) and CDI (n = 72)). GDH testing revealed that 138 samples were negative for C.
difficile (non-colonized; NC), and 33 were positive; C. difficile toxin PCR was positive in 21 of
the latter samples (toxigenic C. difficile; TCD) and negative in 12 (non-toxigenic C. difficile;
NTCD). 18 samples were excluded due to PCR inhibition or missing data. To obtain data from
patients with symptomatic CDI, we included 64 patients who were diagnosed with CDI in clin-
ical routine testing (diarrhea and Clostridium difficile toxin ELISA and/or standard toxigenic
culture technique positive). 8 samples had to be excluded due to PCR inhibition or missing
data.
There were significantly more females in the CDI group compared to the TCD group
(Table 1, p<0.01). The age between the groups was similar. As expected, CDI patients suffered
from recent diarrhea more often than NC, NTCD or TCD patients (p<0.001). There was no
difference in the previous history of CDI between the groups. Previous exposure to antibiotics
was least common in the NC group as compared to the NTCD group (p<0.05), the TCD
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group (p<0.05) or the CDI group (p<0.01). No difference in the use of acid suppressive drugs
was observed between the groups.
Prevalence and relative abundance of the baiCD gene cluster
Endpoint PCR measurements for detecting the baiCD genes showed baiCD positivity rates of
72.5% (100/138) in NC, 58.3% (7/12) in NTCD, 61.9% (13/21) in TCD and 35.9% (23/64) in
CDI samples (Fig 1A). Comparing the prevalence of baiCD-positive fecal samples of asymp-
tomatic (NC, NTCD, TCD) and symptomatic (CDI) patients, the prevalence was significantly
higher in the NC group (p< 0.0001) and in the TCD group (p = 0.0447) compared to the CDI
group (Fig 1A). In comparison, the prevalence of baiCD-positive fecal samples did not signifi-
cantly differ between colonized (NTCD and TCD) and non-colonized (NC) patients. Further-
more, no differences were seen between colonization with a toxigenic or non-toxigenic strain.
To obtain an estimate of the abundance of baiCD-positive bacteria in the samples tested
positive for the baiCD genes, copy numbers were compared (Fig 1B). Quantification of the
baiCD-positive samples showed no significant differences between the three asymptomatic
groups and CDI (p = 0.2827, Fig 1B). The median copy number was 1.3 x 103 copies/μl stool
suspension for NC (min. 2.19 x 100 to max. 1.5 x 105), 1.1 x 103 copies/μl stool suspension for
NTCD (min. 3.9 x 100 to max. 4.4 x 104), 3.8 x 103 copies/μl stool suspension for TCD (min.
Table 1. Baseline characteristics.
Patient characteristics NC (n = 138) NTCD (n = 12) TCD (n = 21) CDI (n = 64) TOTAL (n = 235)
Female (n, %) 72 (52.2) 5 (41.7) 6 (28.6) 39 (60.9) 122 (51.9)
Age (years, mean±SD) 61.2±14.96 57.67±15.88 63.57±12.11 62.62±19.42 61.6±15.98
Diarrhea (3 months; n, %) 34 (24.6) 4 (33.3) 6 (28.6) 64 (100.0)# 108 (46.0)
Past CDI episode (3 months; n, %) 3 (2.2) 0 (0.0) 0 (0.0) 2 (3.1) 5 (2.1)
Antibiotics (3 months; n, %) 38 (27.5) 7 (58.3) 11 (52.4)¶ 25 (39.1)§ 81 (34.5)
aminoglycoside 0 (0) 0 (0) 1 (9.1) 1 (4) 2 (2.5)
penicilline±beta-lactamase inhibitors 14 (36.8) 2 (28.6) 5 (45.5) 13 (52) 34 (42)
carbapenem 3 (7.9) 1 (14.3) 5 (45.5) 7 (28) 16 (19.8)
cephalosporin 5 (13.2) 1 (14.3) 2 (18.2) 9 (36) 17 (21)
quinolone 13 (34.2) 3 (42.9) 4 (36.4) 8 (32) 28 (34.6)
colistin 0 (0) 0 (0) 0 (0) 1 (4) 1 (1.2)
glycopeptide 1 (2.6) 0 (0) 3 (27.3) 7 (28) 11 (13.6)
glycoside 2 (5.3) 0 (0) 0 (0) 3 (12) 5 (6.2)
glycylcycline 1 (2.6) 0 (0) 0 (0) 0 (0) 1 (1.2)
lincosamide 0 (0) 0 (0) 0 (0) 2 (8) 2 (2.5)
oxazolidone 0 (0) 0 (0) 2 (18.2) 1 (4) 3 (3.7)
macrolide 0 (0) 2 (28.6) 2 (18.2) 3 (12) 7 (8.6)
nitroimidazole 9 (23.7) 1 (14.3) 2 (18.2) 4 (16) 16 (19.8)
sulfonamide 8 (21.1) 1 (14.3) 1 (9.1) 1 (4) 11 (13.6)
unknown 0 (0) 1 (14.3) 0 (0) 0 (0) 1 (1.2)
PPI (3 months; n, %) 90 (65.2) 8 (66.7) 12 (57.1) 26 (40.6) 136 (57.9)
PPI: Proton pump inhibitor; SD: Standard deviation;
: p<0.01 (TCD vs. CDI);
#: p<0.001 (NC/TCD/NTCD vs. CDI);
: p<0.05 (NC vs. NTCD);
¶: p<0.05 (NC vs. TCD);
§: p<0.01 (NC/NTCD vs. CDI)
https://doi.org/10.1371/journal.pone.0196977.t001
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3.2 x 101 to max. 2.8 x 105) and 3.1 x 102/μl stool suspension (min. 4.3 x 100 to max. 1 x 106) for
CDI (Fig 1B).
Next, we sought to evaluate the abundance of baiCD genes in relation to the total bacterial
load. For a subgroup of C. difficile-negative and CDI patients who were baiCD-positive, the
baiCD gene cluster copy number was compared to the total 16S rDNA copy number as a mea-
sure for the total bacterial load and the relative abundance of baiCD genes was calculated (Fig
2). The ratio baiCD/16S rDNA was determined for each individual sample and the median
was computed for each subject group. There was no significant difference between the rela-
tive abundances of both groups (p = 0.3244). The median of the NC group was 6.03x10-5
(4.97x10-6–3.76x10-3) and for the CDI group 9.44x10-5 (2.4x10-6–7.81x10-2). This indicates
that when baiCD gene cluster is detectable, there is no difference in relative baiCD gene clus-
ter abundance between C. difficile negative and CDI fecal samples.
16S rDNA quantification in different stool consistencies
When comparing asymptomatic and CDI patients, different stool consistencies have to be
anticipated. To examine whether stool consistency affects the total bacterial concentration, we
performed 16S rDNA qPCR in stool samples of different consistencies [Bristol stool scale
(BSS) 1–4, BSS 5–6 and BSS 7]. For proof of principle, we tested nine stool samples of BSS 1–4,
18 stool samples of BSS 5–6 and 19 stool samples of BSS 7 (Fig 3).
The median of the nine stool samples with a BSS 1–4 was 7.25 x 106 copies/μl stool suspen-
sion (min. 9 x 105 to max. 1.8 x 107), the median of the 18 stool samples with a BSS 5–6 was
3.09 x 106 copies/μl (min. 1.04 x 106 to max. 1.35 x 107), and the median of the 19 stool samples
of BSS 7 was 1.9 x 106 copies/μl (min. 3.7 x 104 to max. 2.7 x 107). The widest range of copy
numbers was seen in the patient samples with a BSS of 7. There was no significant difference
between the copy numbers in different stool consistencies (p = 0.1194). This indicates that
stool consistency does not measurably influence the relative abundance of bacterial species in
this context of complex microbial communities.
Fig 1. BaiCD gene cluster prevalence/abundance and C. difficile state. The prevalence/abundance of the baiCD gene cluster was analyzed in
fecal samples of patients with C. difficile infection (CDI, n = 64), colonization with non-toxigenic C. difficile (NTCD, n = 12), toxigenic C.
difficile (TCD, n = 21), and of C. difficile-negative (NC, n = 138) patients by species-specific qPCR. Fig 1A: End-point qPCR revealed a
significantly higher prevalence of baiCD genes in NC and TCD than in CDI samples ( p<0.0001,  p<0.05, chi-square test and Fisher´s
exact test). Fig 1B: BaiCD gene cluster copy numbers were not statistically different in baiCD-positive NC (n = 96), NTCD (n = 6), TCD
(n = 12) and CDI (n = 21) samples (box-and-whiskers plot, median-IQR-min/max, one-way ANOVA, p = n.s. (non-significant)).
https://doi.org/10.1371/journal.pone.0196977.g001
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FMT cases, outcome and the occurrence of baiCD genes
Given the high risk of recurrence and the importance of microbiome perturbances for the
pathogenesis of CDI, fecal microbiota transplantation has been associated with high success
rates in several clinical studies on patients suffering from rCDI, and incorporated in interna-
tional CDI guidelines [31, 57].
Patient 1 was a 35-year-old Caucasian female who presented with multiple episodes of
recurrent CDI due to multiple antibiotic usage for several reasons over a 6-month period (con-
firmed by positive C. difficile ELISA testing). Sequential treatment with metronidazole, vanco-
mycin, and fidaxomicin had failed. The patient was treated with 250 ml fecal suspension of the
patient’s spouse via colonoscopy. She could be discharged on the same day and was symptom-
free after three days. During a followed-up period (3 months and one year later), the patient
was still C. difficile toxin negative.
Patient 2 was a 72-year-old Caucasian female who presented with multiple episodes of
recurrent CDI after treatment with clindamycin for erysipelas. At initial diagnosis, the patient
Fig 2. BaiCD gene cluster abundance in relation to the total bacterial load. The ratio baiCD/16S rDNA was
determined for a subset of baiCD-positive fecal samples. No significant difference in the relative baiCD gene cluster
abundance between NC (C. difficile negative) and CDI (C. difficile infection) samples could be detected (n = 9 in each
group; box-and-whiskers plot, median-IQR-min/max, one-way ANOVA, p = n.s.).
https://doi.org/10.1371/journal.pone.0196977.g002
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suffered from pseudomembranous colitis with bloody-slimy diarrhea 10 times daily and
abdominal cramps. All approved antibiotics for treatment of CDI failed. We performed FMT
with 250 ml fecal suspension of the patient’s son-in-law via colonoscopy. After FMT, the
patient immediately was symptom-free. During a followed-up period (11 days and 42 days
later), the patient was still C. difficile toxin negative and free of symptoms.
The FMT procedure was well tolerated in both patients and no adverse or severe adverse
events were noticed. Since patient two came from a more distant location and was completely
symptom-free after the treatment, the pre-scheduled follow-up visit was missed.
We performed qPCR for the baiCD genes in fecal samples of the patients before FMT and
during the follow-up period as well as of the donor at baseline and performed agarose gel elec-
trophoresis of the qPCR products (Fig 4). Patient 1 showed no baiCD positivity at baseline and
during follow-up. The patient’s donor was baiCD-negative as well. Patient 2 was baiCD-nega-
tive at baseline and became baiCD-positive during follow-up. The donor was baiCD-positive.
Discussion
Intestinal dysbiosis can disrupt mechanisms of CDI resistance, which is thought to include a
decrease of bile acid 7α-dehydroxylating microbial species, leading to reduced secondary bile
acid biosynthesis [58–60]. The genes required for this metabolic step have been located in a
single bile acid inducible (bai) operon in C. scindens as well as in C. hiranonis. This is the first
Fig 3. Total bacterial concentration and stool consistency. 16S rDNA qPCR quantification as a measure of the total
bacterial concentration was carried out in samples of three different stool consistencies, namely BSS (Bristol Stool
Scale) 1–4 (constipated/normal), 5–6 (unformed/liquid), and 7 (diarrhea). 16S rDNA abundance was not statistically
different between the groups (box-and-whiskers plot, median-IQR, one-way ANOVA: p = 0.1194).
https://doi.org/10.1371/journal.pone.0196977.g003
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study investigating the relationship of the baiCD gene cluster and C. difficile colonization/
infection in human fecal samples.
Our experiments show that we could not only identify the baiCD-positive species C. scin-
dens and C. hiranonis in a species-specific PCR, but also quantify the copy numbers in just one
run. The specificity of our baiCD gene cluster PCR primer pair was verified by detecting a sin-
gle PCR product using DNA from bile acid 7α-dehydroxylating bacterial strains (S3 Fig) and
extensive sequence comparisons with sequence databases.
It is known that in the setting of a disrupted microbiota during C. difficile infection, the
number of bile acid 7α-dehydroxylating microbial species is decreased with consecutively
reduced secondary bile acid concentrations and increased primary bile acids as a potent germi-
nant for C. difficile [12, 58–61]. However, data on the prevalence of baiCD-positive species in
fecal samples is sparse. Kitahara et al. examined 34 samples of healthy individuals using direct
Fig 4. Presence of the baiCD gene cluster in 2 patients before and after fecal microbiota transplantation (FMT). Agarose gel
loaded with products of an end-point PCR detecting the baiCD gene cluster (92 bp) of C. scindens and C. hiranonis (positive
control, lane 2+3; negative controls: lane 4+5). In patient 1 (lanes 6–9), baiCD gene cluster was neither detected before, nor after
FMT or in the donor. Patient 2 (lanes 10–13) was baiCD-negative before the procedure, but persistently positive after receiving
FMT from a baiCD-positive donor. (Lane 1+14: 1 kbp and 50 bp DNA ladder; NTC = non-template control)).
https://doi.org/10.1371/journal.pone.0196977.g004
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PCR. The authors found C. scindens in 27, and C. hiranonis in 18 samples [62]. Recently, an
association between colonization resistance to C. difficile and the presence of C. scindens
(among other species) was reported on the basis of a murine infection model and a small
number of hematologic patients (n = 12) [30]. However, evidence on the prevalence of baiCD-
positive species in the context of C. difficile colonization or infection, and during FMT in
patients—both of which would potentially provide clues regarding their relevance for C. diffi-
cile-associated colonization resistance—is lacking. In our study, the prevalence of baiCD posi-
tivity was indeed higher in non-CDI samples as compared to CDI samples. It has to be kept in
mind, however, that we analyzed patients admitted to the hospital, and that the prevalence of
the baiCD gene cluster may be influenced by pre-treatments (e.g. antibiotics, immunosuppres-
sion), pre-hospitalization as well as by different diseases. There were no significant differences
in the prevalence of the baiCD genes between NC, NTCD and TCD samples, even though the
prevalence was numerically higher in NC samples than the colonized ones. Contrary to our
expectations, significant differences in the prevalence could be seen between TCD and CDI.
However, the number of GDH positive and toxin PCR positive non-CDI-samples was too
small to draw firm conclusions. The idea that baiCD-carrying bacteria play a role not only in
C. difficile infection but also in colonization is intriguing and has to be tested in a larger
sample.
Recently, Studer et al. showed that in gnotobiotic mice harboring a simplified murine
12-species "oligo-mouse microbiota", which represents the major murine intestinal bacterial
phyla, but is deficient for 7α-dehydroxylation, the addition of C. scindens significantly
decreased C. difficile colonization and pathogenesis [63]. 24h and 72h after infection with C.
difficile, C. scindens and C. difficile densities as well as the cecal luminal bile acid composition
were measured. 24 h post infection the C. scindens-associated mice showed partial resistance
against C. difficile colonization associated with the secondary bile acid deoxycholic acid (DCA)
in the cecal contents, whereas 72 h post infection, a complete loss of protection was observed,
associated with a near-complete absence of microbial bile acid transformation products. At
this time point, median C. scindens densities were decreased, but not zero.
These data seem to indicate that not only the presence but also the abundance of C. scindens
could play a role in infection resistance [30]. We therefore analyzed the baiCD gene cluster in
comparison to the total 16S rDNA copy number in the baiCD-positive samples of each group.
Overall, the relative baiCD abundance was not significantly different between C. difficile nega-
tive and CDI fecal samples (Fig 2). Our results thus support the notion that the relevant factor
for C. difficile resistance is the mere presence of the baiCD gene cluster, while the relative gene
copy number seems less important. In the study by Studer and colleagues, the addition of C.
scindens had only minor effects on total bacterial composition [63]. This is in line with the esti-
mate that only a small number of fecal bacteria (~0.0001%) have the ability to convert bile
acids [17, 19, 64, 65].
Thus, our measurements reflect only a small number of species and focus on one special
enzyme in a complex pathway of bile acid conversion. The total number of bacteria involved
in secondary bile acid transformation can be expected to be higher. Furthermore, the number
of 7α-dehydroxylating bacteria could be influenced—besides by antibiotic-induced microbiota
disruption—by concomitant diseases. Berr et al. could show that cholesterol gallstone patients
had approximately 1,000-fold higher fecal levels of 7α-dehydroxylating bacteria with high
levels of secondary bile acids compared to patients with lower deoxycholic acid levels [23].
Besides cholesterol gallstones, it was demonstrated that patients with colon cancer had higher
levels of fecal bile acids and concentrations of 7α-dehydroxylating clostridia in their stool [66,
67]. Within bacteria with 7α-dehydroxylating activity, Doerner et al. could show that these
bacteria could be divided into high and low activity groups with an activity range greatly
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(>100-fold) among different strains [24]. For example, C. sordellii belonged to the group of
“low activity” strains, whereas species such as C. scindens had 100-fold greater bile acid 7α-
dehydroxylating activity in vitro.
As to a potential bias introduced by the different stool consistencies present in our samples,
reliable data on the total bacterial concentrations in the presence and absence of diarrhea
using modern molecular methods has not been published. A study in IBS-D patients revealed
a somewhat reduced abundance of aerobic vs. anaerobic bacteria [68]. In a small series of
ETEC-infected patients, no consistent changes in the total number of 16S rRNA sequences
during the diarrheal episode were observed [69]. Rather than on the total bacterial load, several
studies focused on the microbial diversity in diarrheal samples: Vandeputte et al. observed that
stool consistency is associated with fecal microbial richness with the lowest in diarrheal sam-
ples [70]. Our data demonstrated that stool consistency in our cohort does not have any influ-
ence on the total 16S rDNA copy number. However, different numbers of copies of the 16S
rRNA gene can occur in each bacterium, and this number can also vary between different
phyla. There are species with only one copy of this gene, whereas other species harbor up to 15
copies of the 16S rRNA gene [71]. Indeed, we could not make a statement about bacterial rich-
ness but supporting our findings, Tigchelaar et al. did not confirm the results of Vandeputte
et al. association of BSS with microbial richness in a larger cohort [72].
Fecal microbiota transplantation is known to support the correction of the bile acid imbal-
ance occurring in rCDI patients [73]. We therefore hypothesized that the recovery from rCDI
is associated with an acquisition of baiCD genes, and analyzed the prevalence of baiCD genes
in two patients who underwent FMT for rCDI. Both patients were baiCD-negative at baseline
(before FMT), but one patient became baiCD-positive at the least on day 11 after FMT. Inter-
estingly, this patient’s donor was baiCD-positive, and may therefore have transferred baiCD-
positive species (in our case C. scindens and C. hiranonis) to the transplanted individual. In
2015, Weingarden and colleagues examined the short- and long-term bacterial composition
following FMT for rCDI [74]. She found that while the microbiota of the recipients’ samples
was highly correlated to the microbiota of the donors’ samples on day 1, there was high fluctu-
ation within and across patients after the initial time point. Khoruts et al. showed that by 14
days post transplantation, the fecal bacterial composition of the recipient was highly similar to
that of the donor and was dominated by Bacteroides spp. strains and an uncharacterized buty-
rate producing bacterium [75]. While these and other published data indicate that the proba-
bility of baiCD gene cluster transfer in our patient was high, the future development of the
individual microbiota is not well predictable, as it involves the pattern of the donor micro-
biome, but also the recovering recipient’s microbiome. A long time follow up will be needed to
clarify whether the transferred baiCD-positive species will stay or disappear over time. Obvi-
ously, we do not have fecal samples of this patient representing the baseline situation, i. e. the
microbiota composition before the occurrence of CDI (and FMT). It is theoretically conceiv-
able that the patient was baiCD-positive before developing rCDI, that the respective species
were suppressed due to the infection, and that afterward her microbiota recovered, leading to
the detection of baiCD. Furthermore, it is certainly possible that FMT led to the (re-) appear-
ance of other or additional species mediating CDI resistance [30, 76, 77]. Since we analyzed
only fecal samples of two patients, the results must be interpreted carefully. For more statistical
power, a larger cohort of fecal samples of patients undergoing FMT is required.
While there is a solid body of evidence pointing to a key role of bile acid metabolism in this
context, Lawley et al [78] restored the microbiota in mice after antibiotic treatment and C. dif-
ficile infection with a mixture of six phylogenetically diverse intestinal bacteria, and demon-
strated that 7α-dehydroxylating species are not a conditio sine qua non to resolve relapsing
Clostridium difficile infection. In support of this, the work of Studer et al. showed that a
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complex consortium of bacteria and not only some species are responsible for CDI resistance
[63, 78]. Together with published evidence, our results thus indicate that baiCD-positive spe-
cies with the ability to mediate the conversion of primary to secondary bile acids may be one,
but not the only factor in the incompletely understood system of CDI resistance. To add even
more to the complexity, a recently published work showed that sterile fecal filtrate is able to
induce CDI resistance or resolve CDI symptoms [79].
One limitation of our study is the heterogeneous sample size of the different groups, which
may lead to statistical bias. On the other hand, this represents the distribution of non-colo-
nized, colonized and toxin PCR positive individuals in an unselected cohort of patients admit-
ted to the hospital. While the cases presented here offer the perspective that baiCD positivity
could be transferred via FMT, this will have to be confirmed in a larger sample.
Conclusion
In conclusion, our study shows that fecal samples of CDI patients are less frequently baiCD-
positive than samples from C. difficile-negative individuals. This supports the hypothesis that
baiCD-positive species are involved in the complex framework of C. difficile colonization
resistance.
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S1 Fig. Reproducibility of 16S rDNA copy number density by rtPCR. S1A Fig: A serial dilu-
tion starting with 108 copies to 102 copies of the standard (complete 16S gene Escherichia coli
ATCC 25922) was used to determine the reproducibility of the 16S PCR assay as a double
determination on three different days. Non-template controls (NTC) were included in all tests.
The repeated measurements demonstrated a high reproducibility, independent of the techni-
cians and sample types. S1B Fig shows the Ct values of four different fecal samples, measured
as a double determination on three different dates.
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S2 Fig. Alignment with annotated sequences of the baiCD genes. Pairwise comparison of
different baiCD gene cluster sequences. Red colors showed highly (> 96%) matched sequences
in comparison to the less well matched blue fields of sequences. The strains of C. scindens VPI
12708 and C. scindens VE202-05 were different, but the baiCD gene cluster sequence is 100%
consistent.
(TIF)
S3 Fig. Establishment of a species-specific primer PCR against non-target test bacteria.
S3A Fig: Cross-reaction experiments with 10 ng DNA of different bacterial strains (red) dem-
onstrated primer specificity for the baiCD genes of C. scindens (blue) and C. hiranonis (blue)
with Ct values of 16.64 (C. scindens) and 18.01 (C. hiranonis), respectively. Yellow: Non-tem-
plate control (NTC), orange: Blind sample, dark green: Automatically calculated threshold.
S3B Fig: The corresponding melting curves for this experiment showed slightly different melt-
ing peaks for C. hiranonis and C. scindens.
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